Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Waverly Advisors LLC

by · The Cerbat Gem

Waverly Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 54.4% in the first quarter, Holdings Channel reports. The firm owned 9,628 shares of the medical research company’s stock after acquiring an additional 3,393 shares during the period. Waverly Advisors LLC’s holdings in Amgen were worth $2,737,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Amgen by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after acquiring an additional 3,045,657 shares during the last quarter. Capital International Investors raised its stake in Amgen by 547.8% during the 1st quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock valued at $1,991,738,000 after acquiring an additional 5,923,915 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Amgen by 3.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock valued at $1,890,769,000 after acquiring an additional 243,720 shares during the last quarter. Royal Bank of Canada raised its stake in Amgen by 14.8% during the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after acquiring an additional 751,947 shares during the last quarter. Finally, Norges Bank purchased a new stake in Amgen during the 4th quarter valued at approximately $1,556,912,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $0.50 during midday trading on Tuesday, hitting $333.01. 808,559 shares of the company’s stock were exchanged, compared to its average volume of 2,640,851. Amgen Inc. has a twelve month low of $228.21 and a twelve month high of $346.85. The firm has a market cap of $178.64 billion, a P/E ratio of 47.50, a PEG ratio of 2.78 and a beta of 0.58. The stock’s 50 day moving average price is $314.32 and its 200-day moving average price is $297.45. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. During the same quarter in the previous year, the company earned $3.98 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 19.5 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Truist Financial reissued a “buy” rating and set a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Argus increased their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Mizuho increased their target price on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. William Blair raised Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, Morgan Stanley dropped their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average target price of $312.63.

Check Out Our Latest Research Report on AMGN

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).